Ethical and Safety Issues

[1]  A. Daar,et al.  Introducing New Technologies: Protecting Subjects of Surgical Innovation and Research , 2003, World journal of surgery.

[2]  S. Hoffman,et al.  Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. , 1999, Human gene therapy.

[3]  T. Friedmann,et al.  Gene Therapy for Human Genetic Disease? , 1972, Science.

[4]  P. Gonin,et al.  Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development , 2004, Gene therapy.

[5]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[6]  S. Akira,et al.  Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Jo Wixon,et al.  Gene therapy clinical trials worldwide to 2007—an update , 2007, The journal of gene medicine.

[8]  D. Klinman,et al.  The regulation of DNA vaccines. , 2001, Current opinion in biotechnology.

[9]  T. Kimman,et al.  Preclinical and Clinical Safety Studies on DNA Vaccines , 2006, Human vaccines.

[10]  Philippe Duclos,et al.  Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS , 2009, Expert review of vaccines.

[11]  S. Bougeard,et al.  In vivo tissue distribution and kinetics of a pseudorabies virus plasmid DNA vaccine after intramuscular injection in swine. , 2007, Vaccine.

[12]  R. Haworth,et al.  The Assessment of Local Tolerance, Acute Toxicity, and DNA Biodistribution Following Particle-Mediated Delivery of a DNA Vaccine to Minipigs , 2002, Toxicologic pathology.

[13]  C. Bona,et al.  Genetic immunization of neonates. , 2002, Microbes and infection.

[14]  C. Densmore,et al.  Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  R. G. Joosten,et al.  Persistence of DNA studied in different ex vivo and in vivo rat models simulating the human gut situation. , 2004, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[16]  C. Cavard,et al.  Correction of mouse ornithine transcarbamylase deficiency by gene transfer into the germ line. , 1988, Nucleic acids research.

[17]  W. W. Nichols,et al.  Plasmid DNA Vaccines: Tissue Distribution and Effects of DNA Sequence, Adjuvants and Delivery Method on Integration into Host DNA , 2001, Intervirology.

[18]  G. Dickson,et al.  Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 , 2009, Proceedings of the National Academy of Sciences.

[19]  M. Son,et al.  Safety Evaluation of GX-12. A New DNA Vaccine for HIV Infection in Rodents , 2003, Drug and chemical toxicology.

[20]  O. Cohen-Haguenauer.  Gene therapy: regulatory issues and international approaches to regulation. , 1997, Current opinion in biotechnology.

[21]  J. Kimmelman,et al.  The ethics of human gene transfer , 2008, Nature Reviews Genetics.

[22]  R. Curtiss,et al.  Degradation of DNA by nucleases in intestinal tract of rats. , 1977, Science.

[23]  R. Crystal,et al.  Progress and prospects: gene therapy for performance and appearance enhancement , 2008, Gene Therapy.

[24]  R. Scheule,et al.  CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  L. Walters.  The ethics of human gene therapy , 1986, Nature.

[26]  S L Hoffman,et al.  Do DNA vaccines induce autoimmune disease? , 1997, Human gene therapy.

[27]  Adam Bagg,et al.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.

[28]  E. Nabel,et al.  Immunotherapy for cancer by direct gene transfer into tumors. , 1994, Human gene therapy.

[29]  B. Williams,et al.  Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways , 2003, Nature Medicine.

[30]  Nathalie Simard,et al.  The road to licensure of a DNA vaccine. , 2007, Current opinion in investigational drugs.

[31]  R. Kurth.  Risk Potential of the Chromosomal Insertion of Foreign DNA , 1995, Developments in biological standardization.

[32]  H. Koyama,et al.  Impact of non-homologous end-joining deficiency on random and targeted DNA integration: implications for gene targeting , 2008, Nucleic acids research.

[33]  K. Cichutek.  DNA Vaccines: Development, Standardization and Regulation , 2001, Intervirology.

[34]  Frøydis Gillund,et al.  Do uncertainty analyses reveal uncertainties? Using the introduction of DNA vaccines to aquaculture as a case. , 2008, The Science of the total environment.

[35]  R. Scheule,et al.  Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  W. W. Nichols,et al.  Plasmid DNA Vaccines: Investigation of Integration into Host Cellular DNA following Intramuscular Injection in Mice , 2001, Intervirology.

[37]  W. Kim,et al.  Safety Evaluation of GX-12, a New HIV Therapeutic Vaccine: Investigation of Integration into the Host Genome and Expression in the Reproductive Organs , 2003, Intervirology.

[38]  T. Kessis,et al.  Expression of HPV16 E6 or E7 increases integration of foreign DNA. , 1996, Oncogene.

[39]  M. Bureau,et al.  Intramuscular plasmid DNA electrotransfer: biodistribution and degradation. , 2004, Biochimica et biophysica acta.

[40]  L. Walters.  Ethical Issues in Human Gene Therapy , 1991, The Journal of Clinical Ethics.

[41]  C. Andrews,et al.  Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[42]  K. Ishii,et al.  Factors associated with the development of neonatal tolerance after the administration of a plasmid DNA vaccine. , 1999, Journal of immunology.

[43]  D. Kaslow,et al.  I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. , 2005, Human gene therapy.

[44]  Dexi Liu,et al.  Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA , 1999, Gene Therapy.

[45]  Sören Andersson,et al.  Gene immunization may induce secondary antibodies reacting with DNA. , 2004, Vaccine.

[46]  Fabian Filipp.  Is science killing sport? , 2007, EMBO reports.

[47]  G. Mor,et al.  Plasmid DNA vaccines , 2001, Molecular biotechnology.

[48]  John P. Moore,et al.  A STEP into Darkness or Light? , 2008, Science.

[49]  Isaac Rabino,et al.  Gene Therapy: Ethical Issues , 2003, Theoretical medicine and bioethics.

[50]  W. W. Nichols,et al.  Potential DNA Vaccine Integration into Host Cell Genome , 1995, Annals of the New York Academy of Sciences.

[51]  R A Houghten,et al.  Induction of neonatal tolerance by plasmid DNA vaccination of mice. , 1996, The Journal of clinical investigation.

[52]  K. Loeb,et al.  Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  S. Hoffman,et al.  Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. , 1999, Human gene therapy.

[54]  T. C. Tonheim,et al.  DNA vaccination in aquaculture — Expert judgments of impacts on environment and fish health , 2008 .

[55]  C. Andrews,et al.  Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[56]  T. Jensen,et al.  Physiological effects of human growth hormone produced after hydrodynamic gene transfer of a plasmid vector containing the human ubiquitin promotor , 2002, Journal of Molecular Medicine.

[57]  N. Wade.  UCLA gene therapy racked by friendly fire. , 1980, Science.

[58]  G. Ciliberto,et al.  Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation , 2004, Gene Therapy.

[59]  Seng H. Cheng,et al.  Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy , 2004, Expert opinion on drug delivery.

[60]  E. Nabel,et al.  Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. , 1992, Human gene therapy.

[61]  G. Anderson.  Ethical Preparedness and Performance of Gene Therapy Study Co-Ordinators , 2008, Nursing ethics.

[62]  D. Pharm,et al.  European Association of Hospital Pharmacists (EAHP) Guidance on the Pharmacy Handling of Gene Medicines , 2007 .